JPMorgan Chase & Co. Purchases 94,268 Shares of Astrana Health, Inc. (NASDAQ:ASTH)

JPMorgan Chase & Co. increased its position in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 136.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,532 shares of the company’s stock after purchasing an additional 94,268 shares during the period. JPMorgan Chase & Co. owned 0.29% of Astrana Health worth $5,156,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. KBC Group NV lifted its holdings in shares of Astrana Health by 108.4% in the 4th quarter. KBC Group NV now owns 2,530 shares of the company’s stock worth $80,000 after buying an additional 1,316 shares during the period. US Bancorp DE raised its position in shares of Astrana Health by 3,880.0% during the 4th quarter. US Bancorp DE now owns 4,776 shares of the company’s stock worth $151,000 after purchasing an additional 4,656 shares during the last quarter. Moran Wealth Management LLC raised its holdings in Astrana Health by 21.5% in the 4th quarter. Moran Wealth Management LLC now owns 7,944 shares of the company’s stock valued at $250,000 after acquiring an additional 1,404 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of Astrana Health by 4.7% in the 4th quarter. Handelsbanken Fonder AB now owns 8,900 shares of the company’s stock valued at $281,000 after buying an additional 400 shares during the period. Finally, Olympiad Research LP purchased a new stake in Astrana Health in the fourth quarter valued at approximately $287,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Down 4.0 %

Shares of ASTH stock opened at $31.38 on Friday. Astrana Health, Inc. has a 52-week low of $23.12 and a 52-week high of $63.20. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 1.37 and a beta of 1.04. The firm’s 50-day moving average is $32.14 and its 200-day moving average is $39.48. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The firm had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Sell-side analysts predict that Astrana Health, Inc. will post 1.15 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on ASTH shares. Truist Financial dropped their price objective on Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Robert W. Baird lowered their price target on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Barclays initiated coverage on Astrana Health in a report on Tuesday, April 1st. They issued an “equal weight” rating and a $36.00 price target for the company. Bank of America cut their price objective on Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus reduced their target price on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Astrana Health presently has an average rating of “Moderate Buy” and an average price target of $53.29.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.